Supplementary data

Pentasaccharide resin glycosides with multidrug resistance reversal activities
from the seeds of *Pharbitis nil*

Jun Li, Wen-Qiong Wang, Shuai Tang, Wei-Bin Song, Min Huang and Li-Jiang Xuan*

*State Key Laboratory of Drug Research, Shanghai Institute of Meteria Medica, Chinese Academy of Sciences, 501 Haike Road, Shanghai 201201, People’s Republic of China
University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, People’s Republic of China*

**Corresponding authors**

* Li-Jiang Xuan:

*E-mail*: ljxuan@simm.ac.cn

Tel/Fax: +86-21-20231968
Contents:

Figures
Figure S1. $^1$H NMR (500MHz, pyridine-$d_3$) spectrum of pharbitin A (1)
Figure S2. $^{13}$C NMR (125MHz, pyridine-$d_3$) spectrum of pharbitin A (1)
Figure S3. $^1$H-$^1$H COSY (500MHz, pyridine-$d_3$) spectrum of pharbitin A (1)
Figure S4. HSQC (500MHz, pyridine-$d_3$) spectrum of pharbitin A (1)
Figure S5. HMBC (500MHz, pyridine-$d_3$) spectrum of pharbitin A (1)
Figure S6. HRESIMS spectrum of pharbitin A (1)
Figure S7. IR (KBr disc) spectrum of pharbitin A (1)
Figure S8. $^1$H NMR (500MHz, pyridine-$d_3$) spectrum of pharbitin B (2)
Figure S9. $^{13}$C NMR (125MHz, pyridine-$d_3$) spectrum of pharbitin B (2)
Figure S10. $^1$H-$^1$H COSY (500MHz, pyridine-$d_3$) spectrum of pharbitin B (2)
Figure S11. HSQC (500MHz, pyridine-$d_3$) spectrum of pharbitin B (2)
Figure S12. HMBC (500MHz, pyridine-$d_3$) spectrum of pharbitin B (2)
Figure S13. HRESIMS spectrum of pharbitin B (2)
Figure S14. IR (KBr disc) spectrum of pharbitin B (2)
Figure S15. $^1$H NMR (500MHz, pyridine-$d_3$) spectrum of pharbitin C (3)
Figure S16. $^{13}$C NMR (125MHz, pyridine-$d_3$) spectrum of pharbitin C (3)
Figure S17. $^1$H-$^1$H COSY (500MHz, pyridine-$d_3$) spectrum of pharbitin C (3)
Figure S18. HSQC (500MHz, pyridine-$d_3$) spectrum of pharbitin C (3)
Figure S19. HMBC (500MHz, pyridine-$d_3$) spectrum of pharbitin C (3)
Figure S20. HRESIMS spectrum of pharbitin C (3)
Figure S21. IR (KBr disc) spectrum of pharbitin C (3)
Figure S22. $^1$H NMR (500MHz, pyridine-$d_3$) spectrum of pharbitin D (4)
Figure S23. $^{13}$C NMR (125MHz, pyridine-$d_3$) spectrum of pharbitin D (4)
Figure S24. $^1$H-$^1$H COSY (500MHz, pyridine-$d_3$) spectrum of pharbitin D (4)
Figure S25. HSQC (500MHz, pyridine-$d_3$) spectrum of pharbitin D (4)
Figure S26. HMBC (500MHz, pyridine-$d_3$) spectrum of pharbitin D (4)
Figure S27. HRESIMS spectrum of pharbitin D (4)
Figure S28. IR (KBr disc) spectrum of pharbitin D (4)
Figure S29. $^1$H NMR (500MHz, pyridine-$d_3$) spectrum of pharbitin E (5)
Figure S30. $^{13}$C NMR (125MHz, pyridine-$d_3$) spectrum of pharbitin E (5)
Figure S31. $^1$H-$^1$H COSY (500MHz, pyridine-$d_3$) spectrum of pharbitin E (5)
Figure S32. HSQC (500MHz, pyridine-$d_3$) spectrum of pharbitin E (5)
Figure S33. HMBC (500MHz, pyridine-$d_3$) spectrum of pharbitin E (5)
Figure S34. HRESIMS spectrum of pharbitin E (5)
Figure S35. IR (KBr disc) spectrum of pharbitin E (5)
Figure S36. $^1$H NMR (500MHz, pyridine-$d_3$) spectrum of pharbitin F (6)
Figure S37. $^{13}$C NMR (125MHz, pyridine-$d_3$) spectrum of pharbitin F (6)
Figure S38. $^1$H-$^1$H COSY (500MHz, pyridine-$d_3$) spectrum of pharbitin F (6)
Figure S39. HSQC (500MHz, pyridine-$d_3$) spectrum of pharbitin F (6)
Figure S40. HMBC (500MHz, pyridine-$d_3$) spectrum of pharbitin F (6)
Figure S41. HRESIMS spectrum of pharbitin F (6)
Figure S42. IR (KBr disc) spectrum of pharbitin F (6)
Figure S43. $^1$H NMR (500MHz, pyridine-$d_5$) spectrum of pharbitin G (7)
Figure S44. $^{13}$C NMR (125MHz, pyridine-$d_5$) spectrum of pharbitin G (7)
Figure S45. $^1$H-$^1$H COSY (500MHz, pyridine-$d_5$) spectrum of pharbitin G (7)
Figure S46. HSQC (500MHz, pyridine-$d_5$) spectrum of pharbitin G (7)
Figure S47. HMBC (500MHz, pyridine-$d_5$) spectrum of pharbitin G (7)
Figure S48. HRESIMS spectrum of pharbitin G (7)
Figure S49. IR (KBr disc) spectrum of pharbitin G (7)
Figure S50 $^1$H NMR (400MHz, pyridine-$d_5$) data of 11-(S-MPTA)-hydroxytetradecanoic acid
Figure S51 $^1$H NMR (400MHz, pyridine-$d_5$) data of 11-(R-MPTA)-hydroxytetradecanoic acid
Figure S52 HRESIMS of 11-hydroxytetradecanoic acid
Figure S53 EIMS of 11-hydroxytetradecanoic acid
Figure S54 HRESIMS of n-octanoic acid
Figure S55 HRESIMS of n-decanoic acid
Figure S56 HRESIMS of trans-cinnamic acid
Figure S57 HRESIMS of 2-methylbutanoic acid
Figure S58 Chiral GC analysis of (R/S)-2-methylbutanoic acid
Figure S59 Chiral GC analysis of (S)-2-methylbutanoic acid
Figure S60 Chiral GC analysis of alkali hydrolysate of pharbitin D (4)
Table S1 Results of Modulating MDR Activities in A549/T Cells of Compound 1-4 and 6
Table S2 Results of Modulating MDR Activities in K562/ADR Cells of Compound 1-4 and 6
Figure S1. $^1$H NMR (500MHz, pyridine-$d_5$) spectrum of pharbitin A (1)

Figure S2. $^{13}$C NMR (125MHz, pyridine-$d_5$) spectrum of pharbitin A (1)
Figure S3. $^1$H-$^1$H COSY (500MHz, pyridine-$d_5$) spectrum of pharbitin A (1)

Figure S4. HSQC (500MHz, pyridine-$d_5$) spectrum of pharbitin A (1)
Figure S5. HMBC (500MHz, pyridine-d$_5$) spectrum of pharbitin A (1)

Figure S6. HRESIMS spectrum of pharbitin A (1)
Figure S7. IR (KBr disc) spectrum of pharbitin A (1)

Figure S8. $^1$H NMR (500MHz, pyridine-$d_5$) spectrum of pharbitin B (2)
Figure S9. $^{13}$C NMR (125MHz, pyridine-$d_5$) spectrum of pharbitin B (2)

Figure S10. $^1$H-$^1$H COSY (500MHz, pyridine-$d_5$) spectrum of pharbitin B (2)
Figure S11. HSQC (500MHz, pyridine-$d_5$) spectrum of pharbitin B (2)

Figure S12. HMBC (500MHz, pyridine-$d_5$) spectrum of pharbitin B (2)
Figure S13. HRESIMS spectrum of pharbitin B (2)

Figure S14. IR (KBr disc) spectrum of pharbitin B (2)
Figure S15. $^1$H NMR (500MHz, pyridine-$d_5$) spectrum of pharbitin C (3)

Figure S16. $^{13}$C NMR (125MHz, pyridine-$d_5$) spectrum of pharbitin C (3)
Figure S17. $^1$H-$^1$H COSY (500MHz, pyridine-$d_5$) spectrum of pharbitin C (3)

Figure S18. HSQC (500MHz, pyridine-$d_5$) spectrum of pharbitin C (3)
Figure S19. HMBC (500MHz, pyridine-\textit{d}_5) spectrum of pharbitin C (3)

Figure S20. HRESIMS spectrum of pharbitin C (3)
Figure S21. IR (KBr disc) spectrum of pharbitin C (3)

Figure S22. $^1$H NMR (500MHz, pyridine-$d_5$) spectrum of pharbitin D (4)
Figure S23. $^{13}$C NMR (125MHz, pyridine-$d_5$) spectrum of pharbitin D (4)

Figure S24. $^1$H-$^1$H COSY (500MHz, pyridine-$d_5$) spectrum of pharbitin D (4)
Figure S25. HSQC (500MHz, pyridine-$d_5$) spectrum of pharbitin D (4)

Figure S26. HMBC (500MHz, pyridine-$d_5$) spectrum of pharbitin D (4)
Figure S27. HRESIMS spectrum of pharbitin D (4)

Figure S28. IR (KBr disc) spectrum of pharbitin D (4)
Figure S29. $^1$H NMR (500MHz, pyridine-$d_5$) spectrum of pharbitin E (5)

Figure S30. $^{13}$C NMR (125MHz, pyridine-$d_5$) spectrum of pharbitin E (5)
Figure S31. $^1$H-$^1$H COSY (500MHz, pyridine-$d_5$) spectrum of pharbitin E (5)

Figure S32. HSQC (500MHz, pyridine-$d_5$) spectrum of pharbitin E (5)
Figure S33. HMBC (500MHz, pyridine-$d_5$) spectrum of pharbitin E (5)

Figure S34. HRESIMS spectrum of pharbitin E (5)
Figure S35. IR (KBr disc) spectrum of pharbitin E (5)

Figure S36. $^1$H NMR (500MHz, pyridine-$d_5$) spectrum of pharbitin F (6)
Figure S37. $^{13}$C NMR (125MHz, pyridine-$d_5$) spectrum of pharbitin F (6)

Figure S38. $^1$H-$^1$H COSY (500MHz, pyridine-$d_5$) spectrum of pharbitin F (6)
Figure S39. HSQC (500MHz, pyridine-$d_5$) spectrum of pharbitin F (6)

Figure S40. HMBC (500MHz, pyridine-$d_5$) spectrum of pharbitin F (6)
**Figure S41.** HRESIMS spectrum of pharbitin F (6)

**Figure S42.** IR (KBr disc) spectrum of pharbitin F (6)
Figure S43. $^1$H NMR (500MHz, pyridine-$d_5$) spectrum of pharbitin G (7)

Figure S44. $^{13}$C NMR (125MHz, pyridine-$d_5$) spectrum of pharbitin G (7)
Figure S45. $^1$H-$^1$H COSY (500MHz, pyridine-$d_5$) spectrum of pharbitin G (7)

Figure S46. HSQC (500MHz, pyridine-$d_5$) spectrum of pharbitin G (7)
Figure S47. HMBC (500MHz, pyridine-$d_5$) spectrum of pharbitin G (7)

Figure S48. HRESIMS spectrum of pharbitin G (7)
Figure S49. IR (KBr disc) spectrum of pharbitin G (7)

Figure S50 $^1$H NMR (400MHz, pyridine-$d_5$) data of 11-(S-MPTA)- hydroxytetradecanoic acid
Figure S51 $^1$H NMR (400MHz, pyridine-$d_5$) data of 11-($R$-MPTA)- hydroxytetradecanoic acid

Figure S52 HRESIMS of 11-hydroxytetradecanoic acid
Figure S53 EIMS of 11-hydroxytetratradecanoic acid

Figure S54 HRESIMS of n-octanoic acid
Figure S55 HRESIMS of \( n \)-decanoic acid

Figure S56 HRESIMS of trans-cinnamic acid
Figure S57 HRESIMS of 2-methylbutanoic acid
Figure S58 Chiral GC analysis of (R/S)-2-methylbutanoic acid
Figure S59 Chiral GC analysis of (S)-2-methylbutanoic acid
Figure S60 Chiral GC analysis of alkali hydrolysate of pharbitin D (4)
### Table S1. Results of Modulating MDR Activities in A549/T Cells of Compound 1-4 and 6

<table>
<thead>
<tr>
<th>Sample</th>
<th>Inhibition ratio % (5μM)</th>
<th>taxel + sample</th>
<th>IC$_{50}$ value (μM)</th>
<th>RF value</th>
</tr>
</thead>
<tbody>
<tr>
<td>3</td>
<td>-0.7</td>
<td></td>
<td>4.8</td>
<td>1.2</td>
</tr>
<tr>
<td>4</td>
<td>1.4</td>
<td></td>
<td>4.9</td>
<td>1.2</td>
</tr>
<tr>
<td>6</td>
<td>11.8</td>
<td></td>
<td>3.7</td>
<td>1.6</td>
</tr>
<tr>
<td>taxel</td>
<td></td>
<td></td>
<td>6.0</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Sample</th>
<th>Inhibition ratio % (2.5μM)</th>
<th>taxel + sample</th>
<th>IC$_{50}$ value (μM)</th>
<th>RF value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>33.7</td>
<td></td>
<td>2.8</td>
<td>2.2</td>
</tr>
<tr>
<td>2</td>
<td>44.0</td>
<td></td>
<td>1.6</td>
<td>3.7</td>
</tr>
<tr>
<td>taxel</td>
<td></td>
<td></td>
<td>6.0</td>
<td></td>
</tr>
</tbody>
</table>

*MDR: multidrug resistance.

*Serial dilutions ranging from 0.6 to 20μM of taxel in the presence or absence of 5 μM sample.

*RF: IC$_{50}$ of taxel alone/IC$_{50}$ of taxel in presence of 5 μM sample.

### Table S2. Results of Modulating MDR Activities in K562/ADR Cells of Compound 1-4 and 6

<table>
<thead>
<tr>
<th>Sample</th>
<th>Inhibition ratio % (5μM)</th>
<th>adriamycin + sample</th>
<th>IC$_{50}$ value (μM)</th>
<th>RF value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>-6.6</td>
<td></td>
<td>16.0</td>
<td>1.3</td>
</tr>
<tr>
<td>2</td>
<td>0.1</td>
<td></td>
<td>19.0</td>
<td>1.1</td>
</tr>
<tr>
<td>3</td>
<td>-5.2</td>
<td></td>
<td>18.4</td>
<td>1.1</td>
</tr>
<tr>
<td>4</td>
<td>-12.1</td>
<td></td>
<td>17.8</td>
<td>1.1</td>
</tr>
<tr>
<td>6</td>
<td>-7.2</td>
<td></td>
<td>18.5</td>
<td>1.1</td>
</tr>
<tr>
<td>adriamycin</td>
<td></td>
<td></td>
<td>20.1</td>
<td></td>
</tr>
</tbody>
</table>

*MDR: multidrug resistance.

*Serial dilutions ranging from 3.1 to 100μM of adriamycin in the presence or absence of 5 μM sample.

*RF: IC$_{50}$ of adriamycin alone/IC$_{50}$ of adriamycin in presence of 5 μM sample.